$RGBP News: SAN DIEGO, January 17, 2018 /PRNewswire/ -- Regen BioPharma Inc. (RGBP) and (RGBPP) continues to develop small molecule drugs that activate NR2F6 and has identified a key structural element whose presence in small molecules seems to be required for activation of NR2F6. These studies were conducted at ChemDiv Inc., the Company's contract research organization. http://www.stockonhighalert.net/2018/01/rgbp-regen-biopharma-incs-medicinal.html
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.